- Home
- LITS vs ABVC Comparison
LITS vs ABVC Comparison
Compare LITS & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LITS | ABVC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 50.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LITS | ABVC |
|---|---|---|
| Price | $1.29 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 610.7K | 55.6K |
| Earning Date | 02-10-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 56.52 |
| 52 Week Low | $1.26 | $0.40 |
| 52 Week High | $9.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | LITS | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 40.96 |
| Support Level | $1.26 | $2.00 |
| Resistance Level | $1.65 | $2.20 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.69 | 22.86 |
Price Performance
Historical ComparisonAbout LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.